YOLFTbeta
Eledon Pharmaceuticals Inc

Eledon Pharmaceuticals Inc

ELDN · NASDAQ · Healthcare / Biotechnology

2.12USD-0.25 (-10.57%)

Price History

Full chart

Market Stats

Previous Close2.37
Open2.46
Day Range2.07 – 2.52
52-Week Range1.35 – 4.60
Volume1.51M
Market Cap217.78M
P/E (TTM)0.00
Forward P/E5.39
EPS-0.89
Dividend Yield0.00%
Beta0.94
50-Day Avg3.32
200-Day Avg3.00

About

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for the prevention of allograft rejection in kidney transplantation and xenotransplantation. The company has a collaboration agreement with eGenesis, Inc.; and a strategic collaboration with NewcelX Ltd. for the development of the NCEL-101 therapy for Type 1 Diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. David-Alexandre C. Gros M.D., Ph.D.
  • Employees33
  • Headquarters19800 MacArthur Boulevard, Irvine, CA, United States, 92612, USA
  • Websitehttps://eledon.com

Leadership

  • Dr. David-Alexandre C. Gros M.D., Ph.D.CEO & Non Independent Director · b. 1972
  • Dr. Steven N. Perrin Ph.D.President, Chief Scientific Officer & Non Independent Director · b. 1966
  • Mr. Paul Sean LittleChief Financial Officer · b. 1965
  • Mr. John HerbergerVice President of Technical Operations
  • Mr. Bryan E. Smith J.D.General Counsel, Corporate Secretary & Chief Compliance Officer · b. 1980
  • Dr. David Hovland Ph.D.Chief Regulatory Officer
  • Ms. Marina EscuderoVP & Head of Clinical Operations
  • Dr. Sepideh HabibiVP and Head of Safety & Pharmacovigilance

Financials

Income Statement

Currency: USD2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue-----000120.00K120.00K0000
Growth (%)---------0.00%-100.00%---
Cost of Revenue--58109.00K35.00K22.00K11.00K182.00K183.00K195.00K373.00K374.00K359.00K-
Gross Profit---58-109.00K-35.00K-22.00K-11.00K-182.00K-183.00K120.00K-373.00K-374.00K-359.00K-
Gross Margin---------152.50%100.00%----
Operating Expense--23.46M45.15M38.09M13.10M14.05M14.00M18.28M36.99M88.06M42.63M70.22M-
Operating Income-9.65M-15.75M-23.46M-45.26M-38.12M-13.12M-14.06M-14.18M-18.46M-36.87M-88.43M-43.00M-70.58M-83.25M
Operating Margin---------15387.50%-30722.50%----
EBITDA-9.64M-15.71M-23.27M-44.98M-6.90M-13.10M-14.05M-15.83M-16.00M-36.67M-39.41M-42.63M-35.39M-45.27M
EBITDA Margin---------13333.33%-30560.00%----
Net Income-9.65M-15.72M-23.30M-45.09M-37.96M-13.12M-14.06M-16.01M-22.81M-34.51M-87.97M-40.33M-36.18M-45.62M
Net Income Margin---------19009.17%-28755.00%----
R&D7.37M12.20M14.58M32.64M25.02M2.02M6.82M8.13M6.13M23.73M27.08M30.31M51.96M66.27M
R&D as % of Total Revenue--------5109.17%19779.17%----
Interest Expense000174.00K00009.66M202.00K462.00K---
Interest Expense % of Total Revenue--------8048.33%168.33%----

Balance Sheet

Currency: USD2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets11.96M32.29M107.74M67.97M29.76M20.89M17.03M10.93M197.19M170.55M92.79M125.89M177.41M169.01M
Total Liabilities51.86M87.55M4.24M6.25M2.90M1.44M2.53M1.47M6.59M6.55M8.61M42.48M59.27M87.92M
Total Equity-39.90M-55.27M103.50M61.72M26.86M19.45M14.49M9.46M190.60M164.00M84.18M83.42M118.14M81.08M
Cash11.69M31.75M105.26M24.02M23.22M17.23M12.97M8.79M114.19M84.83M56.41M4.61M20.55M22.81M
Total Debt----3.45M--324.00K144.00K769.00K746.00K383.00K954.00K641.00K
Net Debt-11.69M-31.75M-105.26M-24.02M-19.78M-17.23M-12.97M-8.47M-114.05M-84.06M-55.66M-4.23M-19.59M-22.17M

Cash Flow

Currency: USD2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-9.33M-15.48M-21.12M-41.24M-36.52M-14.94M-11.89M-13.86M-15.21M-28.91M-28.42M-39.53M-47.27M-62.34M
Investing Cash Flow-8.00K-53.00K-175.00K-40.51M35.68M23.26M11.04M11.04M11.04M----70.31M10.79M
Financing Cash Flow18.78M35.59M94.80M513.00K37.00K7.87M7.56M9.68M109.58M-449.00K33.02M33.02M133.52M53.81M
Capital Expenditure8.00K23.00K25.00K565.00K17.00K000000000
Free Cash Flow-9.34M-15.50M-21.15M-41.80M-36.54M-14.94M-11.89M-13.86M-15.21M-28.91M-28.42M-39.53M-47.27M-62.34M
Dividends Paid--------25.00K-----
FCF to OCF100.09%100.15%100.12%101.37%100.05%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%
Dividend Paid to FCF---------0.16%-----

Earnings

Report DateNov 10, 2014Mar 12, 2015May 12, 2015Aug 12, 2015Nov 10, 2015Mar 10, 2016May 10, 2016Aug 4, 2016Nov 3, 2016Mar 3, 2017May 3, 2017Aug 9, 2017Nov 8, 2017May 11, 2018Aug 7, 2018Nov 13, 2018Mar 28, 2019May 14, 2019Aug 13, 2019Nov 13, 2019Mar 17, 2020May 15, 2020Aug 14, 2020Nov 16, 2020Mar 30, 2021May 13, 2021Aug 12, 2021Nov 11, 2021Mar 24, 2022May 12, 2022Aug 11, 2022Nov 14, 2022Mar 30, 2023May 11, 2023Aug 10, 2023Nov 9, 2023Mar 28, 2024May 13, 2024Aug 19, 2024Nov 12, 2024Mar 26, 2025May 14, 2025Aug 14, 2025Nov 14, 2025Mar 19, 2026May 7, 2026Aug 13, 2026Nov 13, 2026
EPS Estimate-58.70-55.40-49.81-92.75-81.40-76.54-81.32-86.83-68.85-55.08-48.60-48.60--5.22-5.58-7.20-7.20-8.73-7.65-7.29-4.68-2.88-2.97-1.75-1.76-0.32-3.76-0.65-0.79-0.68-0.72-0.69-0.70-0.74-0.45-0.41-0.39-0.33-0.32-0.31-0.33-0.30-0.23-0.25-0.20-0.26-0.19-0.20
EPS Actual-301.32-45.36-95.58-64.80-85.86-79.38-82.62-97.20-66.42-27.54-27.54-23.76-7.74-6.48-6.12-6.66-8.82-9.36-6.30-3.96-3.24-3.49-2.70-5.51-0.69-0.57-0.50-0.66-0.60-0.69-0.65-0.73-0.69-0.75-0.40-0.35-0.29-0.34-1.06-0.32-0.95-0.08-0.13-0.21-0.10-0.33-0.19-
Surprise-413.32%18.12%-91.89%30.13%-5.48%-3.71%-1.60%-11.94%3.53%50.00%43.33%51.11%--24.14%-9.68%7.50%-22.50%-7.22%17.65%45.68%30.77%-21.18%9.09%-214.86%60.80%-78.13%86.70%-1.54%24.05%-1.47%9.72%-5.80%1.43%-1.35%11.11%14.63%25.64%-3.03%-231.25%-3.23%-189.44%73.33%43.48%16.00%50.00%-26.92%0.00%-
TimingPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hours

Key Statistics & Ratios

Market Cap217.78M
Enterprise Value132.74M
Trailing P/E0.00
Forward P/E5.39
Price / Sales0.00
Price / Book6.70
EPS-0.89
Book Value0.89
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-36.86M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-110.71%
Return on Assets-39.02%
Shares Outstanding81.26M
Shares Float74.60M
Beta0.94
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 6 analystsTarget 9.00
  • Strong Buy
    5
  • Buy
    1

Ownership Breakdown

Institutions
62.53%
Insiders
0.33%
Retail / Other
37.14%

Top Institutional Holders

  • Bvf Inc
    6.29M7.74%
  • BlackRock Inc
    4.38M5.39%
  • Defilade Capital Management, L.P.
    3.53M4.34%
  • Vanguard Capital Management, LLC
    3.29M4.05%
  • Ensign Peak Advisors Inc
    2.46M3.03%
  • Geode Capital Management, LLC
    1.79M2.21%
  • Sphera Funds Management Ltd.
    1.77M2.18%
  • Catalio Capital Management, LP
    1.70M2.09%
  • Zimmer Partners LP
    1.60M1.96%
  • State Street Corp
    1.15M1.42%
  • Awm Investment Company Inc
    1.10M1.35%
  • Jefferies Financial Group Inc
    1.09M1.35%
  • Kingdon Capital Management LLC
    1.04M1.28%
  • Millennium Management LLC
    979.71K1.21%
  • ADAR1 Capital Management LLC
    974.42K1.20%
  • Bank of America Corp
    869.54K1.07%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    2.48M3.06%
  • iShares Russell 2000 ETF
    2.01M2.47%
  • Fidelity Small Cap Index
    836.15K1.03%
  • iShares Russell 2000 Growth ETF
    728.95K0.90%

Stock Splits

  • Oct 5, 20201:18
  • May 11, 20171:9